HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.
Print Friendly, PDF & Email

NCT/Study#

NCT03625037 /

GCT3013-01

A Phase 1/2, Open-Label, Dose-Escalation Trial Of GEN3013 In Patients With Relapsed, Progressive Or Refractory B-Cell Lymphoma

DISEASE GROUP:
Lymphoma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: